{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:08:09Z","timestamp":1788188889175,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00228-019-02739-5","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T17:02:43Z","timestamp":1566234163000},"page":"1621-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Liangyu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-4869","authenticated-orcid":false,"given":"Weiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"2739_CR1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.jfas.2017.11.014","volume":"57","author":"\u00d6\u0130 K\u0131l\u0131\u00e7o\u011flu","year":"2018","unstructured":"K\u0131l\u0131\u00e7o\u011flu \u00d6\u0130, Salduz A, Biri\u015fik F, Bilgili F, Polat G, Kaya \u0130, S\u00fcleyman F, Co\u015fkun M (2018) High rates of psychiatric disorders and below normal mental capacity associated with spastic peroneal flatfoot: a new relationship. J Foot Ankle Surg 57:501","journal-title":"J Foot Ankle Surg"},{"key":"2739_CR2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/89040","volume":"7","author":"GK Thaker Jr","year":"2001","unstructured":"Thaker GK Jr, C.W. (2001) Advances in schizophrenia. Nat Med 7:667\u2013671","journal-title":"Nat Med"},{"key":"2739_CR3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1440-1819.2009.02033.x","volume":"64","author":"T Kenji","year":"2010","unstructured":"Kenji T, Nagahide T, Shinichi S, Nobuhisa M, Kunihiro I, Keizo Y, Hiroyuki K, Tetsuya I, Norio O (2010) Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 64:62\u201369","journal-title":"Psychiatry Clin Neurosci"},{"key":"2739_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pnpbp.2010.08.030","volume":"35","author":"O Shin","year":"2011","unstructured":"Shin O, Seiya M, Tomomi T, Rei K, Kazuaki O, Nobumi M, Yasuyuki F, Jun A, Sachiko T, Yukie I (2011) Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 35:78\u201383","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2739_CR5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11632020-000000000-00000","volume":"26","author":"A Attard","year":"2012","unstructured":"Attard A, Taylor DM (2012) Comparative effectiveness of atypical antipsychotics in schizophrenia. CNS Drugs 26:491\u2013508","journal-title":"CNS Drugs"},{"key":"2739_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fendo.2018.00144","volume":"9","author":"A del Campo","year":"2018","unstructured":"del Campo A, Bustos C, Mascayano C, Acu\u00f1a C (2018) Metabolic syndrome and antipsychotics: the role of mitochondrial fission\/fusion imbalance. Front Endocrinol 9:144","journal-title":"Front Endocrinol"},{"key":"2739_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3949\/ccjm.74.8.597","volume":"74","author":"M Mathews","year":"2007","unstructured":"Mathews M, Muzina DJ (2007) Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med 74:597\u2013606","journal-title":"Cleve Clin J Med"},{"key":"2739_CR8","first-page":"408","volume":"143","author":"O Stein-Reisner","year":"2004","unstructured":"Stein-Reisner O, Preisman O, Alfici S, Melamed Y, Bleich A (2004) A long-acting second generation anti-psychotic\u2014experience in Israel. Harefuah. 143:408\u2013409","journal-title":"Harefuah."},{"key":"2739_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2014.11.008","volume":"25","author":"P Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves P, Ara\u00fajo JR, Martel F (2015) Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 25:1\u201316","journal-title":"Eur Neuropsychopharmacol"},{"key":"2739_CR10","doi-asserted-by":"crossref","unstructured":"Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D (2018) Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial. Diabetes & Metabolic Syndrome: Clinical Research & Reviews S1871402118301061","DOI":"10.1016\/j.dsx.2018.04.015"},{"key":"2739_CR11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev.me.44.020193.001005","volume":"44","author":"GM Reaven","year":"1993","unstructured":"Reaven GM (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44:121\u2013131","journal-title":"Annu Rev Med"},{"key":"2739_CR12","first-page":"495","volume":"21","author":"P-H Hou","year":"2018","unstructured":"Hou P-H, Chen C-P, Geng-Ruei C, Lin Y-L (2018) Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL\/6J mice. Iranian J Basic Med Sci 21:495","journal-title":"Iranian J Basic Med Sci"},{"key":"2739_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","volume":"17","author":"CU Correll","year":"2011","unstructured":"Correll CU, Todd L, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17:97\u2013107","journal-title":"Trends Mol Med"},{"key":"2739_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs 19:1\u201393","journal-title":"CNS Drugs"},{"issue":"Suppl. 27","key":"2739_CR15","first-page":"15","volume":"62","author":"DW Haupt","year":"2001","unstructured":"Haupt DW, Newcomer JW (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62(Suppl. 27):15\u201326","journal-title":"J Clin Psychiatry"},{"key":"2739_CR16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 382:951\u2013962","journal-title":"Lancet."},{"issue":"3","key":"2739_CR17","first-page":"e123","volume":"18","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Revista Espa\u00f1ola de Nutrici\u00f3n Humana y Diet\u00e9tica 18(3):e123","journal-title":"Revista Espa\u00f1ola de Nutrici\u00f3n Humana y Diet\u00e9tica"},{"key":"2739_CR18","unstructured":"Abdulghani MA, Defronzo RA (2010) Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine & Biotechnology 2010(1):476279"},{"key":"2739_CR19","first-page":"102","volume":"16","author":"Q Zheng","year":"2010","unstructured":"Zheng Q, Meng G, Li Y, Deng L (2010) Influences of aripiprazole and olanzapine on glycolipid metabolism of schizophrenia patients. J Clin Psychosom Dis 16:102\u2013103","journal-title":"J Clin Psychosom Dis"},{"key":"2739_CR20","first-page":"384","volume":"4","author":"X Li","year":"2011","unstructured":"Li X, Xing B, Zhang Y, Wu H (2011) Comparison of endoctine and metabolic effects of airpiprazole and olanzapine on the treatment of schizophrenia. Clin Educ Gen Pract 4:384\u2013386","journal-title":"Clin Educ Gen Pract"},{"key":"2739_CR21","first-page":"410","volume":"07","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wen W, Zheng Y, Zhang C, Zou G, Li Y, Yang F (2012) Comparative study on efficacy, weight, blood sugar and blood lipid between ziprasidone and olanzapine in treatment of first-episode female patients with schizophrenia. Pharm Today 07:410\u2013412","journal-title":"Pharm Today"},{"key":"2739_CR22","unstructured":"Liu S, Zou Z (2013) A comparative study of domestic aripiprazole and olanzapine in the treatment of schizophrenia. Chongqing Medicine 2013(29):3548\u20133550"},{"key":"2739_CR23","first-page":"11","volume":"19","author":"M Xiao","year":"2013","unstructured":"Xiao M, Hui D, Yang M, Liu J (2013) A control study of metabolic syndrome induced by atypical antipsychotics in schizophrenia. J Clin Psychosom Dis 19:11\u201313","journal-title":"J Clin Psychosom Dis"},{"key":"2739_CR24","first-page":"183","volume":"22","author":"XU Jian-kang","year":"2013","unstructured":"Jian-kang XU, Xu L, Lu-bin Z, Hong-xia LV, Chang-hong W (2013) Effects of aripiprazole versus olanzapine on glucose and lipid metabolism in first-episode of schizophrenics. Henan Med Res 22:183\u2013187","journal-title":"Henan Med Res"},{"key":"2739_CR25","first-page":"13","volume":"15","author":"C Liu","year":"2014","unstructured":"Liu C (2014) A comparative study of the efficacy of aripiprazole and olanzapine in the treatment of patients with schizophrenia and the effects of glucose and lipid metabolism. The Chinese and foreign health abstract 15:13\u201314","journal-title":"The Chinese and foreign health abstract"},{"key":"2739_CR26","first-page":"369","volume":"27","author":"X Lu","year":"2014","unstructured":"Lu X, Liu S, Tian B (2014) A comparative study of the effects of olanzapine and aripiprazole on glucose and lipid metabolism in first-episode schizophrenia. J Psychiatr 27:369\u2013370","journal-title":"J Psychiatr"},{"key":"2739_CR27","first-page":"30","volume":"1","author":"W Chen","year":"2015","unstructured":"Chen W (2015) Effect of ziprasidone and olanzapine on clinical efficacy and glucose and lipid metabolism in first-episode schizophrenia. J Math Med 1:30\u201331","journal-title":"J Math Med"},{"key":"2739_CR28","first-page":"27","volume":"9","author":"C Gao","year":"2015","unstructured":"Gao C (2015) Effect on aripiprazole and olanzapine in the treatment of schizophrenia and influence on glucolipid metabolism. Chin J Pract Nerv Dis 9:27\u201328","journal-title":"Chin J Pract Nerv Dis"},{"key":"2739_CR29","first-page":"36","volume":"21","author":"S Huang","year":"2015","unstructured":"Huang S, Chen X, Wei M (2015) Comparison of curative effects of two therapeutic drugs on elderly patients with schizophrenia and effects of glycolipid metabolism. Psychologist 21:36\u201337","journal-title":"Psychologist"},{"key":"2739_CR30","first-page":"90","volume":"23","author":"Q Liu","year":"2015","unstructured":"Liu Q, Zhao J, Shen L (2015) Effect of aripiprazole and olanzapine on clinical efficacy and glucose and lipid metabolism in patients with first-episode schizophrenia. Chin J Trauma Disability Med 23:90\u201391","journal-title":"Chin J Trauma Disability Med"},{"key":"2739_CR31","first-page":"929","volume":"12","author":"J Zhao","year":"2015","unstructured":"Zhao J, Li W, Gu X, Ai X, Hua T, Lv L (2015) Effect of low-dose aripiprazole on metabolism and quality of life in patients with schizophrenia taking olanzapine. Chin J New Drugs Clin Remed 12:929\u2013934","journal-title":"Chin J New Drugs Clin Remed"},{"key":"2739_CR32","first-page":"975","volume":"26","author":"B Shucun","year":"2016","unstructured":"Shucun B (2016) Effects of different drugs on treatment of elderly schizophrenia and on glucolipid metabolism. Med J Nat Defend Forces Southw China 26:975\u2013977","journal-title":"Med J Nat Defend Forces Southw China"},{"key":"2739_CR33","first-page":"19","volume":"23","author":"S Wang","year":"2016","unstructured":"Wang S (2016) Comparison of the effects of olanzapine and aripiprazole in the treatment of schizophrenia. Chin J Rural Med Pharm 23:19\u201320","journal-title":"Chin J Rural Med Pharm"},{"key":"2739_CR34","first-page":"600","volume":"24","author":"Y Hui","year":"2017","unstructured":"Hui Y, Gangqiao Q, Yaoyu Y (2017) Effects of aripiprazole and olanzapine on body weight and lipid metabolism in schizophrenia patients. Chin J Prim Med Pharm 24:600\u2013603","journal-title":"Chin J Prim Med Pharm"},{"key":"2739_CR35","first-page":"8","volume":"01","author":"R Sun","year":"2012","unstructured":"Sun R, Xue F, Peng Z, Tan Q (2012) Effects on body mass and metabolism of ziprasidone versus olanzapine in the treatment of schizophrenia. J Psychiatry 01:8\u201310","journal-title":"J Psychiatry"},{"key":"2739_CR36","first-page":"93","volume":"11","author":"J Wu","year":"2017","unstructured":"Wu J (2017) Effects of aripiprazole and olanzapine on body mass and glycolipid metabolism in patients with schizophrenia. World Clin Med 11:93","journal-title":"World Clin Med"},{"key":"2739_CR37","unstructured":"Chen Q, Liu X, Chen Y (2008) Research on efficacy and safety of olanzapine and ziprasidonein the treatment of research on efficacy and safety of olanzapine and ziprasidonein the treatment of schizophrenia. Chin J Hosp Pharm 28(21):1856\u20131858"},{"key":"2739_CR38","first-page":"11867","volume":"24","author":"J Jia","year":"2013","unstructured":"Jia J, Zhang Y (2013) Comparison of effects of different drugs on glucose and lipid metabolism in newly diagnosed patients with schizophrenia. Chin J Clin 24:11867\u201311868","journal-title":"Chin J Clin"},{"key":"2739_CR39","first-page":"365","volume":"38","author":"P Shao","year":"2013","unstructured":"Shao P, Ou J, Wu R, Fang M, Chen H, Xu Y, Zhao J (2013) Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia. J Cent South Univ 38:365\u2013369","journal-title":"J Cent South Univ"},{"key":"2739_CR40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/healthcare10030510","volume":"10","author":"X Chen","year":"2014","unstructured":"Chen X (2014) Clinical efficacy of ziprasidone and olanzapine in the treatment of first-episode schizophrenia and study on the safety of glycolipid metabolism. For All Health 10:510","journal-title":"For All Health"},{"key":"2739_CR41","first-page":"908","volume":"34","author":"S Lv","year":"2014","unstructured":"Lv S, Luo C (2014) Efficacy of ziprasidone and olanzapine in the treatment of elderly patients with schizophrenia and its effect on glucose and lipid metabolism. Chin J Gerontol 34:908\u2013909","journal-title":"Chin J Gerontol"},{"key":"2739_CR42","first-page":"4652","volume":"26","author":"J Hao","year":"2015","unstructured":"Hao J, Chen B, Qin T, Wang L, Wen J (2015) Clinical observation of ziprasidone combined with olanzapine in the treatment of refractory schizophrenia in elderly patients. China Pharm 26:4652\u20134654","journal-title":"China Pharm"},{"key":"2739_CR43","unstructured":"Xiao J (2015) Clinical analysis on ziprasidone and olanzapine in the treatment of early schizophrenia. China Modern Med 22(30):80\u201382"},{"key":"2739_CR44","first-page":"16","volume":"11","author":"Y Xuezhi","year":"2015","unstructured":"Xuezhi Y, Bing LU, Jianqing M, Wan W (2015) Effect of ziprasidone and olanzapine in treatment of newly diagnosed mental patients and its effects on metabolism of glucose and lipid. Modern Chin Doctor 11:16\u201318","journal-title":"Modern Chin Doctor"},{"key":"2739_CR45","first-page":"29","volume":"02","author":"M Yuan","year":"2015","unstructured":"Yuan M, Wu N, Wang J, Yuan B (2015) Therapeutic effect of ziprasidone and olanzapine in elderly patients with schizophrenia and its effect on blood glucose and blood lipid levels. J Int Psychiatry 02:29\u201332","journal-title":"J Int Psychiatry"},{"issue":"27","key":"2739_CR46","first-page":"170","volume":"11","author":"Y Huang","year":"2016","unstructured":"Huang Y, Lou Y (2016) Efficacy of ziprasidone and olanzapine in the treatment of elderly patients with organic brain disorders and its effects on glucose and lipid metabolism. China Pract Med 11(27):170\u2013171","journal-title":"China Pract Med"},{"key":"2739_CR47","unstructured":"Zhou Y (2016) Effect of ziprasidone and olanzapine on glucose and lipid metabolism in patients with first-episode schizophrenia. World Latest Medicine (88)"},{"issue":"14\u201315","key":"2739_CR48","first-page":"19","volume":"23","author":"X Zhao","year":"2017","unstructured":"Zhao X (2017) Effects of ziprasidone and olanzapine on glucolipid metabolism of first-episode schizophrenia patients. J Clin Psychosom Dis 23(14\u201315):19","journal-title":"J Clin Psychosom Dis"},{"key":"2739_CR49","first-page":"107","volume":"21","author":"M Li","year":"2008","unstructured":"Li M, Xie C (2008) Changes of blood glucose and lipid levels in adolescents with first-episode schizophrenia treated with olanzapine and riperidone. J Psychiatry 21:107\u2013109","journal-title":"J Psychiatry"},{"key":"2739_CR50","first-page":"1307","volume":"31","author":"M Zhao","year":"2011","unstructured":"Zhao M, Xie F (2011) Efficacy of olanzapine and risperidone in the treatment of schizophrenia in elderly women and its effect on glucose and lipid metabolism. Chin Rural Health Serv Adm 31:1307\u20131309","journal-title":"Chin Rural Health Serv Adm"},{"key":"2739_CR51","first-page":"1","volume":"113","author":"J Yu","year":"2014","unstructured":"Yu J, Hao Z, Xu P, Wang Z, Lin X, Sun J, Li H (2014) A control of schizophrenia\u2019s metabolic syndrome caused by olanzapine and risperidone. J Clin Psychosom Dis 113:1\u20134","journal-title":"J Clin Psychosom Dis"},{"key":"2739_CR52","first-page":"2557","volume":"36","author":"X Xu","year":"2015","unstructured":"Xu X (2015) Efficacy of olanzapine and risperidone in the treatment of schizophrenia in elderly women and its effect on glucose and lipid metabolism. J Qiqihar Med College 36:2557\u20132558","journal-title":"J Qiqihar Med College"},{"key":"2739_CR53","first-page":"21","volume":"23","author":"W Liu","year":"2017","unstructured":"Liu W (2017) Correlation between metabolic disorder related index and serum adiponectin in schizophrenics caused by olanzapine. J Clin Psychosom Dis 23:21\u201327","journal-title":"J Clin Psychosom Dis"},{"key":"2739_CR54","unstructured":"Wang L, Lv H, Xu J, Ma W (2017) Effects of different atypical antipsychotics on the efficacy, body mass and liposaccharide metabolism in patients with organic mental disorders. J Int Psychiatry 44(1)"},{"key":"2739_CR55","doi-asserted-by":"crossref","unstructured":"Higgins, JPT (2008) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane handbook for systematic reviews of interventions","DOI":"10.1002\/9780470712184"},{"issue":"11","key":"2739_CR56","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2337\/diacare.22.11.1911","volume":"22","author":"M. Fukushima","year":"1999","unstructured":"Fukushima M, Taniguchi A, Sakai M, Doi K, Nagasaka S, Tanaka H, Tokuyama K, Nakai Y (1999) Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care 22(11):1911\u20131912","journal-title":"Diabetes Care"},{"key":"2739_CR57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/136515001317021644","volume":"5","author":"MDHM Jozef Peuskens","year":"2001","unstructured":"Jozef Peuskens MDHM (2001) The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety. Int J Psychiat Clin 5:179\u2013187","journal-title":"Int J Psychiat Clin"},{"key":"2739_CR58","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.euroneuro.2015.06.011","volume":"25","author":"F Bartoli","year":"2015","unstructured":"Bartoli F, Crocamo C, Clerici M, Carr\u00e0 G (2015) Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neuropsychopharmacol 25:1767\u20131774","journal-title":"Eur Neuropsychopharmacol"},{"key":"2739_CR59","first-page":"37","volume":"18","author":"LJ Patricio","year":"2014","unstructured":"Patricio LJ, Diego GA, Jose LL, Cristina LL, Javier MO, Andrea GR, Stefany TC (2014) The role of leptin\/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest 18:37\u201345","journal-title":"Horm Mol Biol Clin Invest"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02739-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T22:27:24Z","timestamp":1664144844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02739-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2739"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02739-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}